Diagnosis and treatment of chronic hepatitis B: 2009 update

Minerva Gastroenterologica e Dietologica

Volumn 55, Issue 1, 2009, Pages 5-22

  Morgan, M ^a   Keeffe, E B ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

chronic; Hepatitis B; Hepatitis B virus

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; BIOLOGICAL MARKER; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS A VACCINE; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; VIRUS DNA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANOREXIA; CANCER RISK; CHRONIC HEPATITIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DELTA AGENT HEPATITIS; DEPRESSION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; FATIGUE; FLU LIKE SYNDROME; HEPATITIS A; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KIDNEY FAILURE; LEUKOPENIA; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LOW DRUG DOSE; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATIENT EDUCATION; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT FAILURE; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

HEPATITIS B, CHRONIC; HUMANS;

EID: 67649337108     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. Park W, Keeffe EB. Diagnosis and treatment of chronic hepatitis B. Minerva Gastroenterol Dietol 2004;50:289- 303.
2. Morgan M, Park W, Keeffe EB. Diagnosis and treatment of chronic hepatitis B: an update. Minerva Gastroenterol Dietol 2007;53:25-41.
3. Keeffe EB, Dieterich DT, Han SB, Jacobson TM, Martin P, Schiff ER et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol 2008;6:1315-'sl.
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J Hepatol 2009;50:227-42.
5. Liaw Y-F, Leung N, Kao J-H, Piratvisuth T, Gane E, Han K-H et al, Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008;2:263-83.
6. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007;45:507-39.
7. Ganem D, Prince AM. Hepatitis B vims infection natural history and clinical consequences. N Engl J Med 2004;350:1 118-29.
8. Dienstag JL. Hepatitis B virus infection. N Engi J Med 2008;359: 1486-500.
9. Iloeje UH, Yang HI, Su J, Jen CL, You SL. Chen CJ. Predicting cirrhosis risk hased on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130:678-86.
10. Chen CJ, Yang HI, SuJ,Jen CL, You SL. Lu SN et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006;295:65-73.
11. Realdi G, Fattovich G, Hadziyannis S. Schalm SW, Almasio H Sanchez-Tapias J et al. Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994;21 :656-66.
12. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992;103:1630-5.
13. Pattovich G, Giustina G, Schalm SW, Hadziyannis 5, Sanchez-Tapias J, Almasio P et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology1995;21:77-82.
14. McMahon BJ, Alward WLM, Hall DB, Heyward WE. Bender TR, Francis DP et al. Acute hepatitis B vims infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis 1985;151:599-603.
15. Tassopoulos NC, Papaevangelou GJ, Sjogren MH, Roumeliotou-Karayannis AR, Germ JL, Purcell RH. Natural history of acute hepatitis B surface antigen- positive hepatitis in Greek adults. Gastroenterology 1987;92:1844-50.
16. Chu CJ, Keeffe EB, Han SH, Perrillo RP, Mm AD, Soldevila-Pico C et al. Prevalence of HBV pre-core/core promoter variants in the United States. Hepatology 2003;38:619-28.
17. Nguyen MH, Trinh HN, Garcia RT, Phan J, Nguyen GH, Nguyen K et al. Very high prevalence of pre-core (preC) and/or basal core promoter (BCP) mutations (MUT) in HBeAg-positive (eAg+) and negative (eAg-) chronic hepatitis B (CHB) especially among older patients labstract]. Hepatology 2007;46:674A.
18. Chu CJ, Hussain M, Lok ASF. Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology 2002;36: 1408-15.
19. Werle B, Wursthorn K, Peterson j, Bowden 5, Locarnini 5, Lao G et al. Quantitative analysis of hepatic HBV cccDNA during the natural history of chronic hepatitis B and adefovir dipivoxil therapy: an international multicenter study labstracd. Hepatology 2002;36:296A.
20. Wang C, Lim LY, Deobner H, Tapia K, Lao AW, Manansala JN et al. Factors predictive of significant hepatic fibrosis in adults with chronic hepatitis B. J Clin Gastroenterol 2008;42:820-6.
21. Tsang PS, Trinn H, Garcia RT, Phan JT, Ha NB, Nguyen H et al. Significant prevalence of histologic disease in patients with chronic hepatitis B and mildly elevated serum alanine aminotransferase levels. Clin Gastroenterol Hepatol 2008;6:509-74.
22. Lal M, Hyatt BJ, Nasser I, Corry M, Afdahl N. The clinical significance of persistently normal ALT in chronic hepatitis B. J Hepatol 2007:47:760-7.
23. Prati D, Taioli E, Zanella A, Della Torre E. Botelli S. Dcl Vecchio E et al. Updated definitions of healthy ranges for serum alanine aminotransferase levels. Ann Intern Med 2002;137:1-9.
24. Kim HC, Nam CN, Jee SH, Han KH. Oh DK. Sob I. Normal serum aminotransferase concentration and risk of mortality from liver disease: prospective cohort study. BMJ 2004;328:983-9.
25. Ferrell L, Thiese N, Scheuer H Acute and chronic viral hepatitis. In: McSween R, Bort A, Portmann B, Ishak K. Scheuer F, Anthony P, editors. Pathology of the liver, 4th ed. London: Churchill Livingstone; 2002. p. 313-62.
26. Buckley A, Petrunia D. Practice guidelines for liver biopsy. Canadian Association of Gastroenterolog . Can J Gastroenterol 2000:14:481-2.
27. Lok AS, Heathcote, EJ, Hoofnagle JH. Management of hepatitis B: 2000 - summary of a workshop. Gastroenterology 2001120:1828-53.
28. Yim HJ, Lok ASH Natural history of chronic hepatitis B virus infection: what we knew in 1981 and what we know now in 2005. Hepatology 2006;43:5173-81.
29. Liaw YE, Tsai St.. Pathogenesis and clinical significance of acute exacerbations and remissions in patients with chronic hepatitis b virus infection. Viral Hep Rev 1997;3:143-54.
30. McMahon BJ. Hepatocellular carcinoma and viral hepatitis. In: Wilson BA, ed. Viral Hepatitis. New York: Marcel Dekker;1997:315-30.
31. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol 2002;35:S86-9l.
32. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 2005;42: 1208-36.
33. Johnson PJ, Williams R. Serum aipha-fetoprotein estimations and doubling time in hepatocellular carcinoma: influence of therapy and possible value in early detection. J Cancer Inst 1980;64:1329-32.
34. SheuJC, SongJL, Chen DS, Yang PM, Lai MY. Lu CS et al. Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985 89:259-66.
35. Sherman M, Peltekian KM, Lee CL. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995;22:423-37.
36. Zoli M, Magalotti D, Bianchi G, Goeli C, Marchesini G, Pisi E. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 1996;78:977-85.
37. Oka H, Kurioka N, Kim K, Kanno T, Kurioki T, Mizoguchi Y et al. Prospective study of early detection of hepatocellular carcinoma. Hepatology 1990;12:680-7.
38. Cottone M, Turn H. Caltagirone NI, Parisi P. Orlando A, Fiorentino G et al. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alpha-fetoprotein. J Hepatol 1994;21:1029-34.
39. Colombo M, Dc Franchis R, Del Ninno E. Sangiovanni A, Dc Fazio C, Tommasini M et al. Hepatocellular car cinoma in Italian patients with cirrhosis. N EngI J Med 1991;325:675-80.
40. Keeffe EB. Acute hepatitis A and B in patients with chronic liver disease: prevention with vaccination. Am J Med 2005;118:21S-275.
41. Kumar M, Satapathy 5, Monga R, Das K, Hissar 5, Pande C et al. A randomized controlled trial of lamivudine to treal acute hepatitis B. Hepatology 2007;45:97-101.
42. Tassopuulus NC, Koutcluu MG, Polychrunaki H, Paraloglou-Ioannides M, Hadziyannis SJ. Recombinant interferon-alpha therapy for acule hepalilis B: a randomized, double-blind, placebo-controlled Irial. J Viral Hepal 1997;4:387-94.
43. Toni N, Hasegawa K, Ogawa M, Hashimo F, Hayashi N. Effectiveness and long-term oulcome of lamivudine therapy for acute hepatitis B. Hepalol Res 2002;24:34.
44. Kondili LA, Osman H, Mutimer D. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat 2004; 11:427-31.
45. Sorell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM et al. National Institutes of Health Consensus Development Conference Statement. Management of Hepatitis B. Ann Intern Med 2009; 150: 104-10.
46. Lau GK, Piratvisuth VT, Luo KX, Marcellin F, Thongsawat 5, Cooksley G et al. Peginterferon alfa2a, lamivudine and the combination for HbeAg-positive chronic hepatitis B. N EngI J Med 2005;352:2682- 95.
47. Chang YE, Gish RG, Dc Man R, Gadano A, Sollano J, Chao YC et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N EngI J Med 2006;354:1001-10.
48. Gish RG, Lok AS, Chang YE, de Man RA, Gadano A, Sollano J et al. Entecavir therapy for up to 96 weeks in patients with HBeAg-positive chronic hepatitis B. Gastroenterology 2007; 133:1437-44.
49. Han SB, Chang T. Chao Y. Yoon SK. Gish RG. Cheinquer H et al. Five years of continuous entecavir for nucleoside-naive HBeAg(+) chronic hepalitis B: results from study ETV-901 labstracti, Hepatology 2008;48:705A-706A.
50. Tenney DJ, Pokornowski KA, Rose RE, Baldick CJ, Eggers BJ, Fang J et al. Entecavir at five years shows long-term maintenance of high genetic barrier Io hepatitis B virus resistance labstractl. Hepatol mt 2008:2:S301- S303.
51. Lai CL, Gane F, Hsu CW, Thongsawat 5, Want Y, Chan V et al. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs lamivudine labstracti. Hepatology 2006;44:222A.
52. van Bommel F, Zolliner B, Sarrazin C, Spengler U, Huppe D, Moller B et al. Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatology 2006;4:318-25.
53. van Bommel F, Wunsche T, Mauss 5, Reinke P, Berqk A, Schurmann D et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 2004;40:1421-5.
54. van Bommel F, Schernick A, Hopf U, Berg T. Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe hepatitis B reactivation. Gastroenterology 2003; 124:586-7.
55. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N EnglJ Med 2008;359:2442-22455.
56. Heathcote EJ, Gane F), deMan BA, Chan 5, Sievert W, Mauss S et al. Two year tenofovir disopoxil fumarate (TDF) treatment and adefovir dipivoxil (ADV) switch data in HBeAg-positive patients with chronic hepatitis B (study 103), preliminary analysis labstract]. Hepatology 2008;48:376A.
57. Verhelst D, Monge M, Meynard JL. Fanconi syndrome and renal failure induced by tenofovir: a first case report. AmJ Kidney Dis 2002;40:1331-3.
58. Marcellin P, Lau GK, Bonino F, Farci P, Hadzizanis 5, Jin R et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAgnegative chronic hepatitis B. N Engl J Med 2004;351:1206-17.
59. Marcellin P, Piratvisuth T, Brunetto M, Bonino F, Lau GKK, Farci P et al. Virological and biochemical response in patients with HBeAg-negative chronic hepatitis B treated with peginterferon alfa-2a(4OKD) with or without lamivudine: results of 4-year follow-up [abstractl. J Hepatol 2008:48(Suppl 2):546.
60. Lai CL, Shouval D, Lok AS, Chang YE, Cheinquer H, Goodman Z et al, Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N EngI) Med 2006;354:1011-20.
61. Lai CL, Gane F, Liaw YF, Hsu CW, Thongsawat 5, Wang Y et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N FnglJ Med 2007;357:2576-88.
62. Han S. Lai CL, Gane F, Liaw Y-F, Thongsawat 5, Wang Y et al. Telbivudine globe trial at year two: efficacy, safety, and predictors of outcome in patients with chronic hepatitis B labstract]. Gastroenterology 2007; 132:A765.
63. Da Silva LC, PinhoJR, Sitnik R, Da Fonseca LF, Carnilho FJ. Efficacy and tolerability of long-term therapy using high lamivudine doses for the treatment of chronic hepatitis B. J Gastroenterol 2001;36:476-85.
64. Wright U. Clinical trial results and treatment resistance with lamivudine in hepatitis B. Semin Liver Dis 2004:24(Suppl 11:31-6.
65. Dienstag JL, Goldin RD, Heathcote FJ, Hann HW, Woessner M, Stephenson SL et al. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124:105-17.
66. Liaw YF, SungJJ, Chow WC, Farrell G, Lee CZ, Yuen H et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Fngl J Med 2004;351:1521-31.
67. Yuen MF, Kato T, Mizokami M, Chan AC, Yuen JC, Yuan H) et al. Clinical outcome and virologic profiles of severe hepatitis B exacerbation due to YMDD mutations. J Hepatol 2003;39:850-5.
68. Nafa 5, Abmed 5, Tavan D, Pichoud C, Berby F, Stuyver L et al. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B. Hepatology 2000;32: 1078-88.
69. Fung 5K, Pietro A, Han SH, Rajender RK, Regev A, Keeffe FB et al. Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005;43:937-43.
70. Mutimer D, Pillay, Shields F, Cane F, Ratcliffe D, Martin B et al. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000;46:107-13.
71. Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antivir Chem Chemother 2001;12:67-71.
72. Hadziyannis 5), Tassopoulos NC, Heathcote F), Chang YE, Kitis G, Rizzetto M et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006;131:1743-51.
73. Keeffe FB, Zeuzem 5, Koff RS, Dietenich DT, FstebanMur R, Gane F) et al. Report of an international workshop: roadmap for management of patients receiving oral therapy for chronic hepatitis B. COn Gastroenterol Hepatol 2007;5:890-7.
74. Bninetto MR, Oliveri F, Rocca G, Criscuolo D. Chiaberge E, Capalbo M et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989;10:198-202.
75. Fattovich G, Brollo L, Alberti A, Pontisso P, Giustina G, Realdi G. Long-term follow-up of anti-HBe-positive chronic active hepatitis B. Hepatology 1988;8:1651-4.
76. Liaw Y. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. J Gastroenterol Hepatol 2002;17:S333-7.
77. Homann C, Krogsgaard K, Pedersen C, Andersson P, Nielsen JO. High incidence of hepatitis B infection and evolution of chronic hepatitis B infection in patients with advanced HIV infection. J Acquir Immune Defic Syndr 1991;4:416-20.
78. Thio CL, Seaberg EC, Skolasky RJr, PhairJ, Visscher B, Munoz A et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter AIDS Cohort Study (MACS). Lancet 2002;360:1921-6.
79. Benhamou Y, Katlama C, Lunel F, Coutellier A, Dohin E, Hamm N et al. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann Intern Med 1996;125:705-12.
80. McMahon MA, Jilek BL, Brennan TP, Shan L, Zhou Y. Wind-Rotolo M et al. The HBV drug entecavir: effects on HIV-1 replication and resistance. N Engi J Med 2007;356:2614-21.
81. Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adult and Adolescents: guidelines for the use of antiretroviral agents in HIV1-infected adults and adolescents. [accessed 2008 November 15, cited 2009 January 221. Available at: http:/Jaidsinfo.nih.gov/.
82. Crockett 5, Keeffe EB. Approach to patients with HBV/HCV coinfection. Current Hepatitis Reports 2008;7: 18-24.
83. Kohrt HE. Ouyang DL. Keeffe EB. Systematic review: lamivudine prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Aliment Pharmacol Ther 2006;24: 1003-16.
84. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC. Tsao CJ et al. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37: 1320-8.
85. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;11:965-91.
86. Terrault N, Roche B, Samuel D. Management of the hepatitis B virus in the liver transplantation setting: A European and an American perspective. Liver Transpi 2005;11:716-32.
87. Farci P Maridas A, Coiana A, I.ai ME. Desmet V, Van Eyken P et al. Treatment of chronic hepatitis D with interferon alfa-2a. N Engi J Med 1994;330:88-94.
88. Niro G, Ciancio A, Gaeta GB, Smedile A, Marrone A, Olivero A et al. Pegylated interferon alph-2b as monotherapy or in combination with ribarvirin in chronic hepatitis delta. Hepatology 2006;44:713-20.
89. Castelnau C, Le Gal F, Ripault MP, Gordien E, MartinotPeignoux M, Boyer N et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology 2006;44:728-35.
90. Xu WM, Cui YT, Wang L, Yang H, Liang ZQ, Li XM et al. Efficacy and safety of lamivudine in late pregnancy for the prevention of mother-child transmission of hepatitis B: a multicenter, randomized, double-blind, placebo-controlled study [abstractl. Hepatology 2004;40:272A-273A.